Prospects for the treatment of preeclampsia
The paper presents current generalized data on the immunological aspects of preeclampsia development and progression and emphasizes the role of immunological maladaptation of the mother to pregnancy with the participation of key factors of the immune system in response to the formation of a semi-allogenic fetus and placenta. The results of recent studies allow us to take a fresh look at therapeutic approaches to managing patients with preeclampsia, by taking into account targeted exposure methods against the most important component of its pathogenesis, in particular to prevent excessive activation of the complement system.Sidorova I.S., Nikitina N.A.
Keywords
preeclampsia
immune system
complement
immune complexes
eculizumab
References
1. Moffett-King A. Natural killer cells and pregnancy. Nat. Rev. Immunol. 2002; 2(9): 656-63.
2. Сухих Г.Т., Мурашко Л.Е. Преэклампсия. М.: ГЭОТАР-Медиа; 2010. 576с. [Sukhikh G.T., Murashko L.E. Preeclampsia. Moscow: GEOTAR-Media. 2010; 576p. (in Russian)]
3. Larsen M.H., Hylenius S., Andersen A.M., Hviid T.V. The 3’-untranslated region of the HLA-G gene in relation to preeclampsia: revisited. Tissue Antigens. 2010; 75(3): 253-61.
4. Medawar P.B. Some immunological and endocrinological problems raised by the evolution of viviparity in vertebrates. Symp. Soc. Exp. Biol. 1953; 7: 320-38.
5. Габелова К.А., Арутюнян А.В., Зубжицкая Л.Б., Опарина Т.И., Парусов В.Н. Фиксированные иммунные комплексы и NO-синтетазная активность плаценты при гестозе. Вестник Российской ассоциации акушеров и гинекологов. 2000; 1: 22-4. [Gabelova K.A., Harutyunyan A.V., Zubzhitskaya L.B., Oparina T.I., Parusov V.N. Fixed immune complexes and NO-synthetase activity of the placenta in gestosis. Vestnik Rossiykoy assotsiatsii akusherov-ginekologov. 2000; 1: 22-4. (in Russian)]
6. Feinberg B.B. Preeclampsia: the death of Goliath. Am. J. Reprod. Immunol. 2006; 55(2): 84-98.
7. Redman C.W., Sargent I.L. Pre-eclampsia, the placenta and the maternal systemic inflammatory response: a review. Placenta. 2003; 24(Suppl. A): S21-7.
8. Sargent I.L., Germain S.J., Sacks G.P., Kumar S., Redman C.W. Trophoblast deportation and the maternal inflammatory response in pre-eclampsia. J. Reprod. Immunol. 2003; 59(2): 153-60.
9. Goswami D., Tannetta D.S., Magee L.A., Fuchisawa A., Redman C.W., Sargent I.L., von Dadelszen P. Excess syncytiotrophoblast microparticle shedding is a feature of early-onset pre-eclampsia, but not normotensive intrauterine growth restriction. Placenta. 2006; 27(1): 56-61.
10. Contro E., Bernabini D., Farina A. Cell-free fetal DNA for the prediction of pre-eclampsia at the first and second trimesters: a systematic review and meta-analysis. Mol. Diagn. Ther. 2017; 21(2): 125-35.
11. Huppertz B., Kadyrov M., Kingdom J.C. Apoptosis and its role in the trophoblast. Am. J. Obstet. Gynecol. 2006; 195(1): 29-39.
12. Сидорова И.С. Преэклампсия. М.: МИА; 2016. 528с. [Sidorova IS Preeclampsia. Moscow: MIA. 2016; 528. (in Russian)].
13. Lapaire O., Holzgreve W., Oosterwijk J.C., Brinkhaus R., Bianchi D.W. Georg Schmorl on trophoblasts in the maternal circulation. Placenta. 2007; 28(1): 1-5.
14. Gammill H.S., Aydelotte T.M., Guthrie K.A., Nkwopara E.C., Nelson J.L. Cellular fetal microchimerism in preeclampsia. Hypertension. 2013; 62(6): 1062-7.
15. Gammill H.S., Nelson J.L. Naturally acquired microchimerism. Int. J. Dev. Biol. 2010; 54(2-3): 531-43.
16. Boddy A.M., Fortunato A., Wilson Sayres M., Aktipis A. Fetal microchimerism and maternal health: a review and evolutionary analysis of cooperation and conflict beyond the womb. Bioessays. 2015; 37(10): 1106-18.
17. Boyon C., Vinatier D. Fetal microchimerism: self and non-self, finally who are we? J. Gynecol. Obstet. Biol. Reprod. 2011; 40(5): 387-98.
18. Regal J.F., Gilbert J.S., Burwick R.M. The complement system and adverse pregnancy outcomes. Mol. Immunol. 2015; 67(1): 56-70.
19. Макацария А.Д., Бицадзе В.О., Хизроева Д.Х., Акиньшина С.В. Тромботические микроангиопатии в акушерской практике. М.: ГЭОТАР-Медиа; 2017. 304с. [Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh., Akinshina S.V. Thrombotic microangiopathies in obstetric practice. Moscow: GEOTAR-Media. 2017; 304p. (in Russian)]
20. Albieri A., Kipnis T., Bevilacqua E. A possible role for activated complement component 3 in phagocytic activity exhibited by the mouse trophoblast. Am. J. Reprod. Immunol. 1999; 41(5): 343-52.
21. Baines M.G., Millar K.G., Mills P. Studies of complement levels in normal human pregnancy. Obstet. Gynecol. 1974; 43(6): 806-10.
22. Derzsy Z., Prohaszka Z., Rigo J. Jr., Fust G., Molvarec A. Activation of the complement system in normal pregnancy and preeclampsia. Mol. Immunol. 2010; 47(7-8): 1500-6.
23. Richani K., Soto E., Romero R., Espinoza J., Chaiworapongsa T., Nien J.K. et al. Normal pregnancy is characterized by systemic activation of the complement system. J. Matern. Fetal Neonatal Med. 2005; 17(4): 239-45.
24. Lokki A.I., Heikkinen-Eloranta J., Jarva H., Saisto T., Lokki M.L., Laivuori H., Meri S. Complement activation and regulation in preeclamptic placenta. Front. Immunol. 2014; 5: 312.
25. Bulla R., Bossi F., Agostinis C., Radillo O., Colombo F., De Seta F., Tedesco F. Complement production by trophoblast cells at the feto-maternal interface. J. Reprod. Immunol. 2009; 82(2): 119-25.
26. Bulla R., Agostinis C., Bossi F., Rizzi L., Debeus A., Tripodo C. et al. Decidual endothelial cells express surface-bound C1q as a molecular bridge between endovascular trophoblast and decidual endothelium. Mol. Immunol. 2008; 45(9): 2629-40.
27. Mohlin F.C., Mercier E., Fremeaux-Bacchi V., Liszewski M.K., Atkinson J.P., Gris J.C., Blom A.M. Analysis of genes coding for CD46, CD55, and C4b-binding protein in patients with idiopathic, recurrent, spontaneous pregnancy loss. Eur. J. Immunol. 2013; 43(6): 1617-29.
28. Salmon J.E., Heuser C., Triebwasser M., Liszewski M.K., Kavanagh D., Roumenina L. et al. Mutations in complement regulatory proteins predispose to preeclampsia: a genetic analysis of the PROMISSE cohort. PLoS Med. 2011; 8(3): e1001013.
29. Burwick R.M., Fichorova R.N., Dawood H.Y., Yamamoto H.S., Feinberg B.B. Urinary excretion of c5b-9 in severe preeclampsia: tipping the balance of complement activation in pregnancy. Hypertension. 2013; 62(6): 1040-5.
30. Gou S.J., Yuan J., Wang C., Zhao M.H., Chen M. Alternative complement pathway activation products in urine and kidneys of patients with ANCA-associated GN. Clin. J. Am. Soc. Nephrol. 2013; 8(11): 1884-91.
31. Burwick R.M., Easter S.R., Dawood H.Y., Yamamoto H.S., Fichorova R.N., Feinberg B.B. Complement activation and kidney injury molecule-1-associated proximal tubule injury in severe preeclampsia. Hypertension. 2014; 64(4): 833-8.
32. Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B. et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010; 185(9): 5628-36.
33. Burwick R.M., Burwick N.R., Feinberg B.B. Eculizumab fails to inhibit generation of C5a in vivo. Blood. 2014; 124(23): 3502-3.
34. Guseh S.H., Feinberg B.B., Dawood H.Y., Yamamoto H.S., Fichorova R.N., Burwick R.M. Urinary excretion of C5b-9 is associated with the anti-angiogenic state in severe preeclampsia. Am. J. Reprod. Immunol. 2015; 73(5): 437-44.
35. Lynch A.M., Gibbs R.S., Murphy J.R., Byers T., Neville M.C., Giclas P.C. et al. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am. J. Obstet. Gynecol. 2008; 199: 354. e1-8.
36. Lillegard K.E., Loeks-Johnson A.C., Opacich J.W., Peterson J.M., Bauer A.J., Elmquist B.J. et al. Differential effects of complement activation products c3a and c5a on cardiovascular function in hypertensive pregnant rats. J. Pharmacol. Exp. Ther. 2014; 351(2): 344-51.
37. Wang W., Irani R.A., Zhang Y., Ramin S.M., Blackwell S.C., Tao L. et al. Autoantibody-mediated complement C3a receptor activation contributes to the pathogenesis of preeclampsia. Hypertension. 2012; 60(3): 712-21.
38. Perez-Sepulveda A., Torres M.J., Khoury M., Illanes S.E. Innate immune system and preeclampsia. Front. Immunol. 2014; 5: 244.
39. Weiss G., Goldsmith L.T., Taylor R.N., Bellet D., Taylor H.S. Inflammation in reproductive disorders. Reprod. Sci. 2009; 16(2): 216-29.
40. Santner-Nanan B., Peek M., Khanam R., Richart L., Zhu E., Fazekas de St Groth B., Nanan R. Systemic increase in the ration between FoxP3+ and IL-17 producing CD4+ T cells in healthy pregnancy but not in preeclampsia. J. Immunol. 2009; 183(11): 7023-30.
41. Hsu P., Nanan R.K. Innate and adaptive immune interactions at the fetal-maternal interface in healthy human pregnancy and pre-eclampsia. Front. Immunol. 2014; 5: 125.
42. Darmochwal-Kolarz D., Kludka-Sternik M., Tabarkiewicz J., Kolarz B., Rolinski J., Leszczynska-Gorzelak B., Oleszczuk J. The predominance of Th17 lymphocytes and decreased number and function of Treg cells in preeclampsia. J. Reprod. Immunol. 2012; 93(2): 75-81.
43. Hellerud B.C., Aase A., Herstad T.K., Naess L.M., Kristiansen L.H., Troseid A.M. et al. Critical roles of complement and antibodies in host defense mechanisms against Neisseria meningitidis as revealed by human complement genetic deficiencies. Infect. Immun. 2010; 78(2): 802-9.
44. Hallstensen R.F., Bergseth G., Foss S., Jaeger S., Gedde-Dahl T., Holt J. et al. Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn. Immunobiology. 2014; 220(4): 452-9.
45. Cohn A.C., MacNeil J.R., Clark T.A., Ortega-Sanchez I.R., Briere E.Z., Meissner H.C. et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm. Rep. 2013; 62(22-R): 1-28.
46. Kelly R., Arnold L., Richards S., Hill A., Bomken C., Hanley J. et al. The management of pregnancy in paroxysmal nocturnal haemoglobinuria on long term eculizumab. Br. J. Haematol. 2010; 149(3): 446-50.
47. Burwick R.M., Feinberg B.B. Eculizumab for the treatment of preeclampsia/HELLP syndrome. Placenta. 2013; 34(2): 201-3.
Received 08.09.2017
Accepted 22.09.2017
About the Authors
Iraida S. Sidorova, MD, Professor, Academician of RAS, Honoured Scientist of the Russian Federation, I.M. Sechenov First Moscow State Medical University, Therapeutic Faculty, Department of Obstetrics and Gynaecology № 1. 119991, Russia, Moscow, Trubetskaya str. 8, bld. 2Natalya A. Nikitina, MD, Associate Professor of the Chair of Obstetrics and Gynaecology № 1, I.M. Sechenov First Moscow State Medical University, Therapeutic Faculty, Chair of Obstetrics and Gynaecology № 1. 119991, Russia, Moscow, Trubetskaya str. 8, bld. 2. E-mail: natnikitina@list.ru
For citations: Sidorova I.S., Nikitina N.A. Prospects for the treatment of preeclampsia. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2018; (6): 5-10. (in Russian)
https://dx.doi.org/10.18565/aig.2018.6.5-10
Similar Articles
